Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis by Byszczuk, Przemysaw & Szekanecz, Zoltán
  1Błyszczuk P, Szekanecz Z. RMD Open 2020;6:e001032. doi:10.1136/rmdopen-2019-001032
Review
Pathogenesis of ischaemic and non- 
ischaemic heart diseases in 
rheumatoid arthritis
Przemysław Błyszczuk  ,1,2 Zoltan Szekanecz3
To cite: Błyszczuk P, 
Szekanecz Z. Pathogenesis 
of ischaemic and non- 
ischaemic heart diseases in 
rheumatoid arthritis. RMD Open 
2020;6:e001032. doi:10.1136/
rmdopen-2019-001032
Received 29 August 2019
Revised 17 November 2019
Accepted 22 November 2019
1Center of experimental 
Rheumatology, University of 
Zurich, Schlieren, Switzerland
2Department of Clinical 
immunology, Jagiellonian 
University Medical College, 
Cracow, Poland
3Department of Rheumatology, 
University of Debrecen, Faculty 
of Medicine, Debrecen, Hungary
Correspondence to
Dr Przemysław Błyszczuk;  
 przemyslaw. blyszczuk@ uzh. ch
Rheumatoid arthritis
© Author(s) (or their 
employer(s)) 2020. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published 
by BMJ.
Key messages
 ► Patients with rheumatoid arthritis (RA) are at in-
creased risk of developing ischaemic and non- 
ischaemic heart diseases.
 ► Subclinical pathological changes in heart muscle 
and in coronary microcirculation are common in RA.
 ► High- grade systemic inflammation in RA is an im-
portant cardiac risk factor.
 ► Conventional and biologic antirheumatic medica-
tions may result in beneficial or adverse effects on 
cardiovascular outcomes.
AbstrAct
Rheumatoid arthritis (RA) is characterised by a chronic 
inflammatory condition of the joints, but the comorbidities 
of RA predominantly contribute to the reduced lifespan 
associated with this disease. Clinical data indicate 
that cardiovascular disease is the major comorbidity 
associated with mortality in RA. in this review, we aimed 
to describe the pathogenesis of heart failure in RA. First, 
we emphasised the fundamental differences between 
ischaemic and non- ischaemic heart diseases and referred 
to their relevance in excessive cardiovascular- dependent 
mortality in RA. Second, we highlighted aspects of 
asymptomatic changes in cardiac tissue and in coronary 
blood vessels that are commonly found in patients 
with diagnosed RA. Third, we focused on high- grade 
systemic inflammation as a key trigger of ischaemic and 
non- ischaemic heart diseases in RA, and described the 
implication of conventional and biologic antirheumatic 
medications on the development and progression of heart 
disease. in particular, we discussed the roles of tumour 
necrosis factor- alpha (TNF-α) and anti- TNF-α therapies on 
the development and progression of ischaemic and non- 
ischaemic heart diseases in RA.
InTroduCTIon
Rheumatoid arthritis (RA) refers to an auto-
immune disease of the joints that affects 0.5%–
1.0% of the global population. In this disease, 
virtually all joints, but typically of hands, feet 
and knees become inflamed, causing stiffness, 
pain and eventually destruction of bone and 
cartilage. RA is not limited to joints but often 
affects internal organs. These extra- articular 
comorbidities are responsible for a reduced 
life expectancy. Patients with RA have approx-
imately a 50% increased risk of incident cardi-
ovascular events1 and cardiovascular death.2 
However, it should be acknowledged that in 
some countries, the cardiovascular mortality 
in the RA population has been significantly 
reduced in recent times.3 4
Heart diseases that commonly occur in 
RA can be classified into two major catego-
ries (figure 1). One category refers to isch-
aemic heart diseases, known also as coronary 
heart diseases, which result in insufficient 
blood supply to the heart muscle by coro-
nary arteries, a pathogenic condition termed 
coronary artery disease. Mechanistically, in 
the process of atherosclerosis, atheroscle-
rotic plaques narrow the lumen of arteries, 
causing a reduction in blood flow. A rupture 
of atherosclerotic plaques can cause forma-
tion of blood clots that may locally block coro-
nary blood vessels and lead to acute coronary 
syndrome. Insufficient oxygen supply to the 
myocardium may cause dysfunction or death 
of cardiomyocytes, cells responsible for the 
contractile activity of the heart muscle. Clin-
ical manifestations of coronary heart disease 
are related to the extent of ischaemia. In a 
less acute form, reduced blood supply may 
result in angina, cardiomyopathy or arrhyth-
mias. In a more acute form, complete occlu-
sion of larger arteries may cause myocardial 
infarction and sudden cardiac death.
Heart abnormalities occurring in the 
absence of coronary artery disease are referred 
to as non- ischaemic heart diseases. Typically, 
non- ischaemic heart diseases develop slowly 
over time and are associated with changes in 
cellular composition and architecture of the 
cardiac muscle. Cardiomyopathies represent 
the most common type of non- ischaemic 
heart disease, in which ventricles become 
enlarged and stiff. In the case of dilated 
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Figure 1 Schematic presentation of the development of 
ischaemic and non- ischaemic heart diseases in rheumatoid 
arthritis.
cardiomyopathy, disease can be triggered by intracardiac 
or extracardiac factors. Dilated cardiomyopathy is often 
progressive and eventually requires heart transplantation 
at the end stage of disease. Patients with dilated cardio-
myopathy develop not only left ventricular or biventric-
ular dilatation associated with systolic dysfunction,but 
also heart valve problems, blood clots and arrhythmias 
leading to heart and secondary organ failure. The pheno-
type of dilated cardiomyopathy can be a consequence of 
the ongoing inflammatory processes in the myocardium, 
termed myocarditis. Inflammation in the heart can also 
affect the pericardium (pericarditis) and cause exces-
sive accumulation of fluid that may progress into a life- 
threating condition, ‘cardiac tamponade’, demonstrated 
by an acute loss of ventricular function due to cardio-
genic shock. All these acquired pathogenic conditions of 
the cardiovascular system can occur in patients with RA.
CardIaC InvolvemenT In ra
Subclinical changes in hearts of patients with ra
The majority of patients with RA develop no serious 
cardiac manifestations for many years. Nevertheless, their 
hearts can show subclinical and asymptomatic changes. 
Various non- invasive imaging tools provide accurate 
insight into the structure and function of the cardiovas-
cular system. Technical advantages and limitations of the 
specific imaging techniques are described elsewhere.5 
Data of cardiac MRI and positron emission tomog-
raphy–computed tomography (PET- CT) in patients with 
RA with no diagnosis of cardiovascular disease demon-
strated that up to half showed signs of cardiac fibrosis 
or inflammation.6 7 These changes in the myocardium 
might be responsible for the observed increased left 
ventricular mass in patients with RA.8 Although hearts 
of patients with RA typically show effective pumping, 
the contractile function is often compromised. Reduced 
systolic and diastolic left ventricle functions were found 
in up to 50% of patients with RA without clinical signs 
of cardiac disease.9 10 Furthermore, echocardiography 
studies revealed that RA is also associated with exception-
ally high rates of asymptomatic pericarditis and cardiac 
valvular involvement.11
RA causes subclinical changes also in the coronary 
microcirculation.12 Measurements of myocardial flow 
reserve showed that a third of patients with RA without 
clinical cardiovascular episodes developed cardiac micro-
vascular dysfunction.13 Furthermore, in the absence of 
coronary artery disease, patients with RA showed higher 
prevalence, extent and severity of all types of coronary 
plaques measured by CT angiography.14 Of note, patients 
with RA are twice as likely to experience episodes of 
silent (unrecognised) myocardial infarction.15 These 
subclinical changes in the myocardium and in the coro-
nary system of patients with RA might be responsible for 
serious ischaemic and non- ischaemic complications on 
follow- up.
Clinical manifestations of heart failures in ra
By the time of RA onset, a history of heart failure is not 
more common in the RA population, and only patients 
with new- onset RA are at increased risk of developing 
ischaemic and non- ischaemic heart diseases.16 Further-
more, the clinical presentation of heart failure in RA is 
different from that of the non- RA population. In cases 
of incident heart failure, patients with RA show signifi-
cantly higher mortality despite better cardiac function 
and lower blood pressure.17
Ischaemic heart disease is an important cause of cardio-
vascular death in patients with RA.18 The risk of arterial 
(including peripheral and coronary) disease or myocar-
dial infarction in RA is comparable to that in diabetes 
mellitus.19 20 The incidence of myocardial infarction was 
70% higher than that in the general population and 
corresponded with the incidence of myocardial infarc-
tion in 10- year- older non- RA subjects.19 Following myocar-
dial infarction, patients with RA have poorer long- term 
outcomes compared with individuals without RA21 and 
a higher risk of death at 30 days.22 Patients with RA have 
a twofold increased risk of sudden cardiac death but are 
less likely to report symptoms of angina.15 In the general 
population, sudden cardiac death is usually caused 
by fatal arrhythmias, which is a result of electrophysio-
logical abnormalities in the heart. Patients with early 
arthritis show no increase in incidence of prolonged QTc 
interval, an indicator of arrhythmogenic phenotype.23 24 
Over time, patients with RA progressively develop proar-
rhythmic QTc prolongation; however, this is not associ-
ated with cardiovascular mortality in these patients.23
In RA, the incidence of non- ischaemic heart failure is 
at least as common as the incidence of ischaemic heart 
failure.16 25 It has been suggested that the increased 
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incidence of non- ischaemic heart failure is mainly 
responsible for the excess mortality in patients with RA.25 
However, it remains to be identified which of the non- 
ischaemic heart failure conditions are more prevalent in 
patients with RA.
TradITIonal CardIovaSCular rISk faCTorS In ra
Development of cardiovascular morbidity and mortality 
is dependent on traditional risk factors, such as age, 
gender, hypertension, diabetes, hyperlipidaemia, 
smoking, obesity, physical inactivity, personal cardiac 
history and genetics. Traditional cardiovascular risk 
factors (except smoking and physical activity) are gener-
ally similarly prevalent in patients with RA and in the 
global population.26 Diagnosed hypertension or type 
2 diabetes is associated with a nearly twofold increased 
risk of cardiovascular morbidity in patients with RA.27 
Surprisingly, the impact of certain traditional risk factors 
(eg, male gender, smoking, personal cardiac history or 
physical inactivity) on major cardiovascular outcomes is 
lower in RA compared with non- RA cohorts.26 27 Further-
more, an increased cardiovascular incidence in patients 
with RA has been reported for traditional low- risk factors 
such as low cholesterol levels28 or low body mass index.29 
These paradoxical observations suggest that different 
pathogenic mechanisms are responsible for cardiovas-
cular morbidity and mortality among patients with RA 
compared with the general population.
InflammaTIon aS a drIvIng forCe for hearT dISeaSeS 
In ra
It is widely believed that in RA, a high- grade inflamma-
tion is a key trigger of a cascade of pathogenic events 
leading to life- threatening cardiovascular disease in some 
patients. Clinical data confirmed that systemic inflam-
mation, indicated by elevated serum levels of C reactive 
protein (CRP) at baseline, is an independent prognostic 
biomarker of cardiovascular death in patients with RA.30 
In fact, each period of increased disease activity in the 
joints significantly increases cardiovascular risk by 7%,31 
whereas a low disease activity reduces the risk of the first 
cardiovascular event.32 At the molecular level, proinflam-
matory cytokines tumour necrosis factor- alpha (TNF-α), 
interleukin (IL)-1β, IL-6 and IL-17 have been associated 
with inflammation in RA and with pathogenesis of heart 
disease.
Inflammation and ischaemic heart diseases
Atherosclerosis is associated with local inflammation in 
the vessel wall and can be enhanced by systemic inflam-
mation. Under homeostatic conditions, vascular function 
is maintained by the endothelium, producing vasoactive 
factors, such as nitric oxide. Inflammation reduces the 
bioavailability of nitric oxide and promotes generation 
of reactive oxygen species. Furthermore, various inflam-
matory mediators decrease endothelial barrier function 
and upregulate production of chemokines and adhesion 
molecules that tether and recruit circulating leucocytes 
to promote formation of atherosclerotic plaques. It has 
been postulated that chronic inflammation is implicated 
in the development of atherosclerosis in patients with RA. 
Measurements of carotid intima–media thickness, a surro-
gate marker of atherosclerosis, indeed demonstrated 
that levels of inflammatory markers in the serum corre-
lated with the subclinical atherosclerotic disease score in 
patients with RA.33 A more detailed analysis of carotid 
arteries by ultrasonography pointed to more unstable 
plaques in patients with RA with active disease.34 CT angi-
ography analysis confirmed the presence of more vulner-
able plaques in coronary arteries of patients with RA with 
more active disease.14 Furthermore, increased aortic stiff-
ness (which is a consequence of dysfunctional endothe-
lium) was found in patients with RA with elevated CRP 
levels indicative of systemic inflammation.35 Clinical data 
further confirmed that elevated inflammatory markers 
as well as increased disease activity were associated with 
increased risk of acute coronary events in patients with 
RA.36 Interestingly, the risk of myocardial infarction in 
RA has not been associated with disease activity but with 
CRP level.37 Taken together, these published data suggest 
that chronic high- grade inflammation is a key factor 
promoting atherosclerosis and coronary artery disease in 
patients with RA.
Inflammation and non-ischaemic heart diseases
In contrast to the well- described contribution of systemic 
inflammation to atherosclerosis, its role in the develop-
ment of non- ischaemic heart disease is less well charac-
terised. Active inflammatory processes in the heart may 
lead to excessive myocardial fibrosis causing stiffening of 
the ventricles and thus contribute to systolic and diastolic 
dysfunctions and to cardiac arrhythmia. Cardiac MRI and 
PET- CT data indeed confirmed a correlation between RA 
disease activity and increased myocardial inflammation 
and fibrosis.7 38 Structural changes in the myocardium 
observed with cardiac MRI also correlate with diagnostic 
markers of systemic inflammation.38 Furthermore, high 
disease activity and elevated CRP levels were associated with 
increased prevalence of diastolic heart failure.39 A recent 
large cohort study confirmed that high disease activity and 
elevated inflammatory markers were associated with an 
increased risk of non- ischaemic heart failure (including 
those with preserved ejection fraction) in patients with 
RA.16 Consistent with these observations, patients with RA 
with low disease activity showed unaffected structure and 
function of the cardiac muscle.40 41 One would expect that 
high- grade systemic inflammation is responsible for the 
end- stage heart failure, the non- ischaemic sudden cardiac 
death and the overall cardiac mortality in RA, but the 
supporting clinical data are not yet available.
ImpaCT of medICaTIon on developmenT of hearT 
dISeaSe In ra
Disease- modifying antirheumatic drugs (DMARDs) repre-
sent a major therapeutic option in RA. Conventional 
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synthetic disease- modifying antirheumatic drugs 
(csDMARDs) represent chemical, synthetic, non- selective 
drugs, such as hydroxychloroquine, methotrexate, lefluno-
mide and sulfasalazine. Furthermore, corticosteroids and 
non- steroidal anti- inflammatory medications are also 
commonly used in RA. In contrast to csDMARDs, biologic 
disease- modifying antirheumatic drugs (bDMARDs) block 
specific inflammatory mediators. Anti- TNF-α inhibitors 
represent the most common bDMARDs in RA therapy. 
In some cases, patients with RA receive other biolog-
ical drugs that suppress IL-6 signalling, T and B cells or 
targeted synthetic disease- modifying antirheumatic drugs 
(tsDMARDs), which inhibit Janus kinase (JAK) activity. 
Although long- term treatment with these immunosup-
pressive drugs is not always beneficial for cardiovascular 
outcomes, it is believed that improved medications and 
‘treat- to- target’ approaches are the main reasons for the 
decline in cardiovascular mortality among patients with RA 
in recent years.4 18
It should be noted that classical cardioprotective medi-
cations, such as a low- dose aspirin, statins, folic acid, ACE 
inhibitors and angiotensin II receptor blockers have also 
been introduced to the prevention and therapy of cardio-
vascular diseases in RA,18 and recent data confirmed the 
cardioprotective effect of statins in patients with RA.42
csdmards and cardiovascular diseases
csDMARDs represent the first line of pharmacological 
therapy in RA. Antimalarial drugs (particularly hydrox-
ychloroquine) and methotrexate are cardioprotective in 
most studies.43–45 Hydroxychloroquine may also inhibit 
platelet aggregation and the thrombogenic effects of 
antiphospholipid antibodies.46 In some cases, however, 
antimalarials can induce cardiomyopathies in patients 
with RA.47 The vascular effects of methotrexate may be 
somewhat controversial. Methotrexate itself increases 
the production of the proatherogenic homocysteine. 
Homocysteine is toxic for endothelial cells and stimu-
lates LDL oxidation. On the other hand, methotrexate 
controls systemic inflammation and thus may exert bene-
ficial cardiovascular effects.18 44 48 In some studies, meth-
otrexate reduced rather than aggravated cardiovascular 
risk.43 44 As a mode of action, methotrexate improves 
reverse cholesterol transport and restores inflammation- 
related impairment of cholesterol efflux in RA. In a large 
meta- analysis, methotrexate reduced the risk of major 
adverse cardiovascular events.44 Interestingly, in a recent 
trial in patients without RA with cardiovascular disease, 
methotrexate was unable to prevent cardiovascular 
events.49 Thus, the beneficial effects of methotrexate 
may be observed under inflammatory conditions only. 
Less data are available regarding the possible cardiovas-
cular effects of other csDMARDs. In a case–control study, 
sulfasalazine treatment for RA was associated with a lower 
cardiovascular risk compared with patients with RA who 
never used sulfasalazine, hydroxychloroquine or metho-
trexate.50 Furthermore, treatment with leflunomide was 
associated with a significantly lower rate of myocardial 
infarction in comparison with patients with RA receiving 
other medications.45 In contrast to other csDMARDs, 
leflunomide may, however, increase blood pressure and 
aggravate hypertension.51
csDMARDs can be supplemented by corticosteroid 
therapy, and in case of exacerbation of pain, patients with 
RA also receive non- steroidal anti- inflammatory drugs 
(primarily COX-2 inhibitors). These drugs increase the 
risk of cardiovascular events.18 44 Of note, even short- 
term (1- year) treatment with corticosteroids in patients 
with new- onset RA significantly increased the risk of non- 
ischaemic heart failure.16 It should be acknowledged that 
patients with RA taking non- steroidal anti- inflammatory 
drugs often show high disease activity. Therefore, we 
cannot exclude that the increased risk is due to high 
inflammatory status of these patients, rather than the 
atherogenic potential of these medications.
anti-Tnf-α therapy and heart disease
TNF-α is considered the predominant cytokine governing 
inflammation in RA. The fusion protein of TNF-α recep-
tors linked to the Fc region of human antibody (etan-
ercept) and chimeric (infliximab), fully human (adal-
imumab and golimumab) or modified human (certoli-
zumab–pegol) anti- TNF-α antibodies represent clinically 
used TNF-α antagonists in RA that can effectively reduce 
inflammation and joint damage. It has been hypothesised 
that anti- TNF-α treatment could be useful to treat other 
inflammation- mediated diseases including heart disease. 
Elevated plasma TNF-α levels were found in patients with 
chronic heart failure and were associated with increased 
mortality.52 Mouse data confirmed that overproduction 
of TNF-α in the heart induced myocardial inflammation, 
remodelling, fibrosis and heart failure.53 Unexpectedly, 
clinical trials failed to confirm the beneficial effect of 
anti- TNF-α antagonists etanercept and infliximab on 
patients with chronic heart failure.54 55 In fact, a higher 
dose of infliximab (10 mg/kg) in New York Heart Asso-
ciation class III or IV patients contributed to the wors-
ening of heart failure and to the reduction of lifespan.55 
Consequently, anti- TNF-α therapy is currently not recom-
mended for patients with heart failure.
In light of these data, the question was raised whether 
anti- TNF-α therapy could be harmful for patients 
with RA by promoting heart failure. Results of clinical 
studies provided an ambiguous answer.56 In general, 
most data reported unchanged or slightly reduced risk 
of heart failure and improved survival of patients with 
RA receiving anti- TNF-α treatment.57–59 A more focused 
subgroup analysis showed that anti- TNF-α therapy might 
be beneficial for women58 and younger patients with 
RA,59 but in an elderly population, it might exacerbate 
heart failure and reduce survival.60
Cardiovascular status might be a critical factor for 
the outcomes of anti- TNF-α therapy. A growing body 
of evidence suggests that blocking TNF-α signalling 
could be helpful for patients with RA with good overall 
health status and unaffected cardiac function. It has 
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Figure 2 Dual role of anti- TNF-α therapy on cardiovascular 
risk in rheumatoid arthritis. TNF-α, tumour necrosis factor- 
alpha.
been shown that infliximab improved heart function 
in patients with RA with preserved left ventricular func-
tion.61 Furthermore, a recent large- scale clinical study 
indicated that anti- TNF-α therapy in patients with RA 
effectively reduced the incidence of acute coronary 
syndrome.62 These beneficial effects were, however, 
not observed for postischaemic events.63 It should be 
mentioned that anti- TNF-α therapy in patients with RA 
is associated with a significantly increased risk of devel-
oping hypertension.64
Dosing and duration of anti- TNF-α therapy represent 
factors that might be decisive for cardioprotection versus 
cardiotoxicity. It should be noted that patients with RA 
usually receive doses of etanercept (50 mg once weekly) 
or infliximab (3 mg/kg) that were safe for patients with 
heart failure. Only a fraction of patients with RA non- 
responding to a standard dose of infliximab receive 
this drug at 10 mg/kg. In contrast to etanercept and 
infliximab, other TNF-α inhibitors were not tested in 
patients with heart failure. Recent data demonstrated, for 
example, a decreased incidence of hospitalisation due 
to heart failure in patients with RA treated with adalim-
umab.65 Further studies are, however, needed to prove 
its beneficial effects also in patients with RA with serious 
heart failure.
In summary, anti- TNF-α therapies effectively suppress 
inflammation and prevent progression of RA and thereby 
reduce the risk of cardiovascular episodes. In patients 
with RA with established heart failure, the treatment does 
not improve cardiac function and, in some cases, might 
worsen it (figure 2). It seems that in patients with RA 
without heart failure, TNF-α increases the risk of cardio-
vascular disorders by promoting systemic inflammation. 
In the failing heart, instead, TNF-α might play a cardio-
protective role, but the underlaying mechanisms remain 
unknown.
oTher bdmardS and TSdmardS and hearT dISeaSe
In addition to TNF-α, IL-6 represents another proinflam-
matory cytokine targeted in RA. In the context of the 
development of major adverse cardiovascular events, the 
IL-6 receptor inhibitor tocilizumab was shown to be a safe 
alternative for the TNF-α antagonist etanercept.66
Abatacept and rituximab represent another class 
of bDMARDs, which target antigens on the surface 
of dendritic cells (CD80/86) and B cells (CD20), 
respectively. T cell costimulation inhibitor abatacept is 
prescribed to patients with RA with a worse cardiovascular 
profile; however, it does not affect the risk of developing 
heart failure compared with etanercept.67 Rituximab is 
a humanised chimeric anti- CD20 monoclonal antibody 
preventing B cell activation. Rituximab was shown to 
improve vascular pathophysiology in RA.68 In clinical 
trials, rituximab showed a cardiovascular safety profile 
comparable to anti- TNF-α treatments.69
Some patients with RA receive tsDMARDs JAK inhib-
itors tofacitinib or baricitinib. Both JAK inhibitors have 
been shown to worsen the plasma lipid profile; however, 
data from clinical studies and databases do not suggest an 
increased cardiovascular risk in patients with RA treated 
with these drugs.70 71 It should be mentioned that statins 
can effectively reverse dyslipidaemia in patients with RA 
treated with tofacitinib.72
In summary, all these drugs seem to represent safe 
options for patients with RA with no serious adverse 
effects on the cardiovascular system. On the other hand, 
despite of their anti- inflammatory properties, no marked 
beneficial cardioprotective effects have been observed 
for any class of these medications.
perSpeCTIveS
In recent years, improved treatment strategies, such as the 
treat- to- target approach, successfully reduced cardiovas-
cular risk in RA. Patients with incidental arthritis and low 
disease activity do not need additional non- conventional 
treatments. However, despite advanced antirheumatic 
medication, some patients with RA still show high 
disease activity. Future studies should be more focused 
on targeted, cardioprotective therapies tailored for these 
patients with RA with high disease activity and those with 
established heart failure. Achievement of these goals 
requires a better understanding of RA- related patho-
physiological processes promoting heart failure. Clinical 
studies have already shed some light onto the pathogen-
esis of heart diseases in RA, but the fundamental cellular 
and molecular mechanisms of pathogenesis remain 
obscure. Additional strategies should focus on preclinical 
experimental studies using animal models and ex vivo 
human tissues. Currently, experimental research seems 
to be under- represented in cardiorheumatology. In the 
future, a balanced cooperation between clinical and 
experimental research will be required to identify new 
therapeutic targets and eventually to develop successful 
cardioprotective therapies for patients with RA.
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